DRUG
Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 Analog
Status
Terminated
Phase
Phase 4
Enrollment
2
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The study aims to examine the effectiveness of the short acting GLP-1 analog, Lixisenatide to achieve glycemic control in type 2 diabetes patients, in patients with failure of long acting GLP-1 analog. Patients who fail to achieve significant improvement in diabetes control on basal insulin and Liraglutide will be switched to basal insulin and lixisenatide treatment for 12 weeks. The primary outcomes will be changes in HBA1C and weight.
Interventions
Treatment arms and agents.
DRUG
Basal insulins
patients are on basal insulin treatment
Timeline
From registration to results.
First posted
May 10, 2016
Study start
Jul 12, 2016
Primary completion
Feb 2017
Study completion
Feb 21, 2017
Results posted
Not reported
Registry updated
Apr 7, 2017
Outcomes
What the study measures.
Primary outcomes
Change in hemoglobin A1c
Time frame · 16 weeks
Change in body weight
Time frame · 16 weeks
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- Not reported
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: Type Diabetes Mellitus on combination of basal insulin therapy and GLP1 analog, with secondary failure of non-fasting glycemic control Exclusion Criteria: * Pregnant or lactating woman * Renal failure (eGFR\<30)
Study locations
1 registered sites.
Israel. Showing up to 24 locations stored in the fast local snapshot.
Bildirici Diabetes Center, Laniado Hospital
Netanya, Israel
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Lixisenatide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus
Sanofi · Type 2 Diabetes
Phase 4
Completed
105
2026-07
Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents
Shanghai Zhongshan Hospital · Type 2 Diabetes
Phase 4
Recruiting
1,316
2026-07
Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
Brigham and Women's Hospital · Cardiovascular Events · Type2 Diabetes
Not applicable
Active, not recruiting
781,430
2026-05
iGlarLixi CGM Study in Chinese T2D Individuals After OADs
Sanofi · Type 2 Diabetes (T2D)
Phase 4
Recruiting
678
2026-03
Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes
Yanbing Li · Type 2 Diabetes
Phase 4
Not yet recruiting
324
2026-02
Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease
University Hospital, Toulouse · Parkinson Disease
Phase 2
Completed
156
2025-11
iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)
Sanofi · Type 2 Diabetes Mellitus
Phase 3
Completed
582
2025-09
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University · Cardiovascular Kidney Metabolic Syndrome
Not applicable
Active, not recruiting
23,280,000
2025-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.